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ABSTRACT 
Immunostimulatory CpG DNA was self-assembled to form DNA hydrogels for use as a sustained delivery system for both intercalated 
doxorubicin (DXR) and immunostimulatory CpG motifs for cancer treatment. X-shaped DNA (X-DNA) was designed as a building unit, and 
underwent ligation to form DNA hydrogels. Two types of X-DNA were constructed using four oligodeoxynucleotides each, one containing six 
potent CpG motifs (CpG X-DNA) and the other with none (CpG-free X-DNA). CpG X-DNA was more effective than its components or the 
CpG-free counterpart in terms of the production of tumor necrosis factor- from murine macrophage-like RAW264.7 cells, as well as maturation 
of the murine dendritic DC2.4 cells. The cytotoxic effects of X-DNA, DXR and their complexes were examined in a co-culture system of 
colon26/Luc cells, a murine adenocarcinoma clone stably expressing firefly luciferase, and RAW264.7 cells. DXR/CpG X-DNA showed the 
highest ability to inhibit the proliferation of colon26/Luc cells. DXR was slowly released from CpG DNA hydrogels. Injections of DXR/CpG 
DNA hydrogels into a subcutaneous colon26 tumor effectively inhibited tumor growth. These results show that CpG DNA hydrogels are an 
effective sustained system for delivery of immunostimulatory signals to TLR9-positive immune cells and DXR to cancer cells. 
 
1. Introduction 
 The use of immunostimulatory agents has a long history in cancer chemo/immunotherapy [1]. This is at least partly because the immune 
system, the most powerful system for preventing cancerous cells from propagating, is greatly impaired in cancer patients and reactivation of the 
system is believed to be effective in killing cancer cells. A variety of immunostimulatory agents have been developed and used as adjuvants, and 
their effects have been shown not only in animal models but also in cancer patients [2-4]. Unmethylated cytosine-phosphate-guanine (CpG) 
dinucleotide, or CpG motif, is a well-known pathogen-associated molecular pattern that is a danger signal for the invasion of pathogens, like 
bacteria [5]. The mammalian immune system recognizes it using Toll-like receptor 9 (TLR9) and releases a variety of proinflammatory 
cytokines, including tumor necrosis factor (TNF)- and interleukin (IL)-12 [6-8], leading to the stimulation of both innate and adaptive immune 
responses. These responses have been shown to be effective in inhibiting tumor growth and metastasis in tumor-bearing animal models [9,10]. 
 DNA has a variety of advantages as a drug delivery system. For instance, DNA is highly soluble in aqueous solution, it can be 
chemically synthesized on a large scale, it is highly stable in powder form or in solution if contains no degrading enzymes, it is also 
biodegradable, and capable of binding low-molecular-weight compounds, including anticancer agents. In a previous study, we demonstrated that 
doxorubicin (DXR) can be intercalated into CpG motif-containing plasmid DNA and delivered to metastatic colonies of colon carcinoma cells in 
mouse liver [11]. Thus, DNA is a promising polymer that can be used as a delivery system for immunostimulatory signals and anticancer agents, 
a combination that would be highly effective for tumor chemo/immunotherapy. Plasmid DNA has some advantages for this application, since it 
is simple to prepare and has an abundance of CpG motifs. However, a major drawback is the fast release of DXR from plasmid DNA. Obtaining 
a sustained release rate of DXR from immunostimulatory CpG DNA would greatly increase the potency of such DXR complexed CpG DNA 
preparations in cancer therapy. 
Recent great advances in the technology of developing DNA-based nanostructures have made it possible to design a variety of forms of 
DNA nanoassemblies [12,13]. We have shown that the immunostimulatory activity of CpG DNA is increased by using it to build highly 
branched structures such as Y-shaped DNA [14] and dendrimer-like DNA [15]. Further ligation of structured DNA units, such as X-shaped DNA 
(X-DNA), results in DNA hydrogels [16]. Because hydrogels are a class of drug delivery systems that can control the release rate of incorporated 
drugs either by erosion or diffusion through polymeric matrix [17], DNA hydrogels consisting of CpG DNA are an ideal system for sustained 
release of both the immunostimulatory signal and anticancer agents. 
In the present study, we designed a new highly immunostimulatory DNA unit by incorporating six highly potent CpG motifs into 
X-DNA, and prepared CpG DNA hydrogels by ligation using a DNA ligase. Then, DXR was intercalated into the DNA, and the 
physicochemical and biological activities of the DXR/CpG DNA hydrogels were examined. CpG-free X-DNA was also used to prepare DNA 
complexes to confirm the importance of CpG motifs with regard to biological and anticancer activity. 
 
2. Materials and methods 
2.1. Chemicals 
 RPMI1640 medium, phosphate buffered saline (PBS), and Hanks’ balanced salt solution (HBSS) were obtained from Nissui 
Pharmaceutical (Tokyo, Japan). Fetal bovine serum (FBS) was obtained from MP Biomedicals (Eschwege, Germany). T4 DNA ligase was 
purchased from Promega (Madison, WI, USA). DNase I was purchased from Takara Bio (Otsu, Japan). Doxorubicin hydrochloride was obtained 
from Wako Pure Chemical (Osaka, Japan). Transwell plates, 12 mm in diameter with a pore size of 0.4 µm, were purchased from Corning Costar 
(Tokyo, Japan). All other chemicals were of the highest grade available and used without further purification. 
2.2. Cell cultures 
 The murine macrophage-like cell line RAW264.7 was obtained from the American Type Culture Collection (Rockville, MD, USA). 
Murine adenocarcinoma colon26 that stably expresses firefly luciferase gene was prepared as reported previously [9]. Cells were grown in 
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RPMI1640 medium supplemented with 10 % heat-inactivated FBS, 0.15 % NaHCO3, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 
mM L-glutamine at 37 °C in humidified air containing 5 % CO2. DC2.4, a murine dendritic cell line, kindly donated by Dr. Kenneth Rock 
(Department of Pathology, University of Massachusetts Medical School, MA, USA) was grown in RPMI1640 medium supplemented with 10 % 
heat-inactivated FBS, 0.15 % NaHCO3, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, 1 M non-essential amino acids 
and 1 nM 2-mercaptoethanol. 
2.3. Animals 
 Male ICR mice (4-week-old) and male BALB/c mice (6-week-old) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Animals 
were maintained under conventional housing conditions and all animal experiments were approved by the Animal Experimentation Committee 
of the Graduate School of Pharmaceutical Sciences, Kyoto University. 
2.4. ODN 
 All phosphodiester ODNs, including one labeled with fluorescein isothiocyanate (FITC) at the 5-end, were purchased from Integrated 
DNA Technologies, Inc. (Coralville, IA, USA). Table 1 summarizes the sequences of the ODNs used in this study. Two different sets of four 
ODNs were designed as the components for CpG X-DNA and CpG-free X-DNA, respectively, based on the G/C content, free energy and 
secondary structure as reported previously [18]. The CpG X-DNA possesses 24 CG dinucleotides, including 6 highly immunostimulatory motifs, 
and has no suppressive CpG motifs, whereas the CpG-free X-DNA contains 10 CG dinucleotides, including no highly immunostimulatory 
motifs and 9 suppressive (CCG or CGG) CpG motifs [19]. 
2.5. Preparation of X-DNA 
 X-DNA with 4 base overhangs at all the 5-ends of a palindromic sequence ACGT was prepared as reported previously [16]. In brief, 
four ODNs dissolved in an annealing buffer (10 mM Tris, pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA), and 50 mM NaCl) were mixed 
together in sterile Milli-Q water at a final concentration of 0.5 mM for each ODN. Mixtures were incubated at 95 °C for 5 min, 65 °C for 2 min, 
62 °C for 1 min, then slowly cooled to 4 °C. Formation of X-DNA was confirmed by 3  agarose gel electrophoresis at 100 V for 45 min.  
2.6. Preparation of DNA hydrogels 
 To construct DNA hydrogels, 1 mol X-DNA underwent random ligation using 0.75 units of T4 DNA ligase (Promega, WI, USA). DNA 
hydrogels were prepared at different initial concentrations of DNA (0.1, 0.2 and 0.4 mM). The reaction was carried out at room temperature 
overnight as reported previously [16]. 
2.7. Preparation of DXR/DNA complexes 
 DXR in Milli-Q water was added to the solution of X-DNA. After 1 h incubation at room temperature, the mixture was used as a 
DXR/X-DNA complex without removal of free DXR, because the intercalation of DXR is an equilibrium process [20]. The mixing ratio of DXR 
and X-DNA was fixed at a 1:10 weight ratio, based on the results of preliminary experiments. Then, DXR/X-DNA was ligated using T4 DNA 
ligase as described above. 
2.8. Observation of the inner structure of DNA hydrogels by scanning electron microscopy 
 To observe the inner structure of the DNA hydrogels, they were fixed with 2 % glutaraldehyde at room temperature overnight, 
dehydrated with increasing concentrations of ethanol which was replaced with butyl alcohol, and freeze-dried. The dried material was cracked 
with a knife and the inner structure of the DNA hydrogels was observed using a field-emission scanning electron microscope (FE-SEM: S4700, 
HITACHI, Japan). 
2.9. TNF- release from RAW264.7 cells 
 RAW264.7 cells were plated on 24-well culture plates at a density of 5105 cells/ml (2.5105 cells/well) and cultured for 24 h before use. 
X-DNA or its components were diluted in RPMI (5 g DNA/ml), and added to the cells. In separate experiments, X-DNA or DNA hydrogels 
diluted in RPMI were added to the cells at different concentrations. Cells were incubated for 8 h, and the supernatants were collected and stored 
at -80 C until assayed. The level of TNF- in the supernatant was determined by enzyme-linked immunosorbent assay (ELISA) using an 
OptEIATM set (Pharmingen, San Diego, CA, USA). 
2.10. Cellular uptake of DNA by RAW264.7 cells 
 FITC-labeled ODN was used for the preparation of FITC-labeled single stranded (ss)-, double stranded (ds)- and X-DNA. RAW264.7 
cells were plated on 96-well culture plates at a density of 5105 cells/ml (5104 cells/well) and cultured for 24 h. Cells were then washed twice 
with 100 l PBS, incubated with FITC-DNA for 1 h at 37 °C or 4 °C, harvested, and washed twice with 100 l PBS. Then, the fluorescent 
intensity of the cells was determined by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA) using CellQuest software (version 
3.1; BD Biosciences). 
2.11. Morphological changes in DC2.4 cells 
 DC2.4 cells were plated on 12-well culture plates at a density of 1105 cells/ml (1105 cells/well) and cultured for 24 h. Cells were 
washed with 1 ml PBS before use. DNA hydrogels (50 g/ml) or lipopolysaccharide (LPS; 100 g/ml) in RPMI was added to the cells. After an 
8 h-incubation, the cells were fixed with glutaraldehyde at room temperature for 1 h, dehydrated, replaced with butyl alcohol, and freeze-dried. 
The morphology of the cells was observed using FE-SEM. 
2.12. Proliferation of tumor cells co-cultured with RAW264.7 cells 
 RAW264.7cells (1×105 cells/ml) and colon26/Luc cells (5×104 cells/ml) were placed in the upper and lower chambers of Transwell 
plates, respectively. X-DNA, DXR or their mixture was added to the upper side at a final concentration of 10 g DNA/ml and 1 g DXR/ml, and 
cells were incubated at 37 C for 48 h. Then, colon26/Luc cells in the lower chambers were lysed in 1 ml of cell lysis buffer (0.1 M Tris, 0.05 % 
Triton-X-100, 2 mM EDTA, pH 7.8). A portion of the buffer was mixed with a luciferase assay buffer (Piccagene, Toyo Ink, Tokyo, Japan), and 
the chemiluminescence produced was measured in a luminometer (Lumat LB9507, EG and G Berthold, Bad Wildbad, Germany). The luciferase 
activity was converted to the number of tumor cells as reported previously [21]. 
2.13. Measurement of gel fraction 
 To estimate the gel fraction of DNA hydrogels, i.e., the percentage of X-DNA being ligated to other X-DNA, DNA hydrogels were 
incubated in Milli-Q water at 60 °C for 24 h, and the amount of DNA in the supernatant was measured as free, non-linked X-DNA using a 
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spectrophotometer (UV-1600, Shimadzu, Japan) 
2.14. Measurement of DNA-bound fraction of DXR 
 DXR/DNA hydrogels were incubated in Milli-Q water at 60 °C for 24 h. The concentrations of DNA and DXR in the supernatant were 
estimated by measuring the absorbance of DNA and fluorescence of DXR, respectively, in a spectrophotometer (UV-1600) and in a multilabel 
counter (ARVOTM MX 1420, Wallac, Finland) with excitation and emission wavelengths of 485 and 560 nm, respectively. The concentration of 
DXR in the supernatant was used to estimate the fraction of DXR bound to DNA hydrogels. 
2.15. Stability of DNA hydrogels and DXR release from DXR/DNA hydrogels in serum 
 After incubation of DNA hydrogels at 60 °C for 24 h to remove non-linked X-DNA, DNA hydrogels with or without DXR were 
incubated in 100 l mouse serum at 37 °C. The supernatant was collected, centrifuged at 2000g for 5 sec, and the concentrations of DNA and 
DXR were measured as described above. The degradation rate of hydrogels and the release rate of DXR were estimated from the concentrations 
of DNA and DXR in the supernatant. 
2.16. Antitumor activity of DXR/DNA hydrogels in tumor-bearing mice 
 Colon26/Luc cells (1×106 cells/mouse) were inoculated into BALB/c mice. Then, the mice received intratumoral injections of 5% 
dextrose, DXR (5 g/mouse), DNA hydrogels (50 g/mouse), or DXR/DNA hydrogels (5 g DXR and 50 g DNA/mouse) on days 9 and 16 
after tumor inoculation. The tumor size was measured periodically with calipers. 
2.17. Statistical analysis 
 Differences were statistically evaluated by one-way analysis of variance (ANOVA) followed by the Fisher’s PLSD test for multiple 
comparisons and by Student’s t-test for two groups. A P-value of less than 0.05 was considered to be statistically significant. 
 
3. Results 
3.1. Formation of X-DNA 
 The four ODNs used to prepare X-DNA were named Xa, Xb, Xc, and Xd, respectively. Fig. 1A shows the agarose gel electrophoresis of 
Xa and mixtures of Xa and Xb, Xa, Xb and Xc, and all four ODNs after annealing. The migration distance became shorter as the number of 
ODNs added to the preparations increased. These results suggest that the ODNs added are hybridized to form double stranded DNA, even 
though almost half of the sequence of each ODN is complimentary to the other ODNs. There was one major band in the lane of all four ODNs, 
suggesting that X-DNA is efficiently obtained as previously reported [16]. No significant differences were observed between CpG X-DNA and 
CpG-free X-DNA. Fig. 1B shows the putative structure of CpG X-DNA. 
3.2. TNF- release from RAW264.7 cells by X-DNA 
 To investigate the effect of the X-shape formation on the cytokine production by CpG DNA, a variety of components of CpG X-DNA 
were added to RAW264.7 cells. Fig. 2A shows the concentration of TNF- in the supernatant of cells 8 h after addition of 5g/ml DNA. 
Because the sequences and the numbers of the CpG motif were different among the ODNs used, the numbers of CpG motifs added to cells were 
not identical even though the same amount (5g/ml) of DNA was added. Xa, Xb, Xc and Xd contained 3, 0, 3 and 0 potent CpG motifs, 
respectively, so that the frequency of CpG motifs in the preparation was calculated to be 1, 0.5, 0.67 and 0.5 for one (Xa), two (Xa and Xb), and 
three ODNs (Xa, Xb and Xc), and X-DNA, respectively. All preparations induced significant production of TNF-, with the highest for CpG 
X-DNA. The level of TNF- induced by CpG X-DNA was significantly greater than that produced by other preparations. Much less TNF- 
production was detected when CpG-free X-DNA or its components was added to RAW264.7 cells. 
3.3. Cellular uptake of DNA by RAW264.7 cells 
 To investigate whether the increased immunostimulatory activity of CpG DNA by X-shape formation is mediated by increased cellular 
uptake, the uptake of DNA was examined in RAW264.7 cells using FITC-labeled DNA. Fig. 2B shows the mean fluorescence intensity (MFI) of 
ss-, ds- and X-DNA. The MFI of cells with added FITC-X-DNA was significantly (P<0.05) greater than that with added FITC-ssDNA or 
FITC-dsDNA, suggesting that increased cellular uptake is at least partly involved in the X-shape formation-mediated increase in the 
immunostimulatory ability. 
3.4. Formation of DNA hydrogels 
 X-DNA samples were ligated to each other through the adhesive ends to obtain DNA hydrogels. Fig. 3 shows typical FE-SEM images of 
the inner structure of DNA hydrogels. The images (A, low magnification and B, high magnification) indicated that the gel has a highly ordered 
structure with plenty of space in the gel, and the diameter ranged from about 200 to 1,000 nm. CpG X-DNA was used to obtain DNA hydrogels 
containing the CpG motif (CpG DNA hydrogels). CpG DNA hydrogels were prepared at different concentrations of CpG X-DNA. A higher 
DNA concentration resulted in a high gel fraction: 44.9  7.5, 60.5  1.5 and 72.9  2.4 % gel fractions for the initial concentrations of 0.1, 0.2 
and 0.4 mM, respectively. 
3.5. TNF- release from RAW264.7 cells by DNA hydrogel 
 To estimate the effect of gel formation on cytokine release, CpG X-DNA and CpG DNA hydrogels were added to RAW264.7 cells. In 
general, CpG DNA hydrogels induced higher levels of TNF- than CpG X-DNA; those prepared at an initial concentration of 0.2 or 0.4 mM 
induced a significantly (P<0.05) higher level of TNF- than CpG X-DNA (Fig. 4A). 
3.6. Morphological changes in DC2.4 cells by DNA hydrogels 
 To investigate whether DNA hydrogels induce maturation of dendritic cells, morphological changes in DC2.4 cells, an immature DC cell 
line, were evaluated (Fig. 4B-E). The round shape of DC2.4 cells was changed very little following an 8 h-incubation in culture media (Fig. 4B). 
Addition of LPS, a typical ligand to induce maturation of dendritic cells, markedly changed the shape of the cells to a dendritic form (Fig. 4C), 
indicating that the cells were matured by the stimulus. The addition of CpG DNA hydrogels also induced similar changes (Fig. 4D), whereas 
CpG-free DNA hydrogels exhibited hardly any changes (Fig. 4E). 
3.7. Antiproliferative activity of DXR/X-DNA on tumor cells cocultured with RAW264.7 cells 
 Antiproliferative activity was evaluated by measuring the luciferase activity of colon26/Luc cells cocultured with RAW264.7 cells in 
Transwell systems. When added to RAW264.7 cells, CpG X-DNA or DXR significantly reduced the number of colon26/Luc cells (Fig. 5). 
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CpG-free X-DNA had no significant effect on the number of colon26/Luc cells. The number of colon26/Luc cells treated with DXR/CpG 
X-DNA was significantly smaller than those treated with DXR alone or DXR/CpG-free X-DNA, indicating that DXR and CPG X-DNA have at 
least additive effects on inhibition of the proliferation of colon26/Luc cells. 
3.8. Degradation and DXR release from DXR/DNA hydrogels in serum 
 The gel fraction of DXR/DNA hydrogels (82.7  5.8 %) was higher than that of DNA hydrogels (71.2  2.5 %). About 78 % of added 
DXR was found to be bound to DNA hydrogels. The fraction was reduced by incubation of the gels in mouse serum, and the rate was slower for 
DXR/DNA hydrogels than for those without DXR (Fig. 6A). DXR was gradually released from DXR/DNA hydrogels at a speed comparable 
with the gel degradation (Fig. 6B). 
3.9. Inhibition of colon26/Luc subcutaneous tumor growth by DXR/DNA hydrogels 
 The growth of a colon26/Luc subcutaneous tumor was monitored after intratumoral injections of DXR, DNA hydrogels or DXR/DNA 
hydrogels. Fig. 7 shows the growth of tumor tissues in mice. Injections of CpG-free DNA hydrogels had no significant effects on tumor growth, 
whereas CpG DNA hydrogels had some effect. Injections of DXR were also effective for the first 4 weeks but, thereafter, the tumor started to 
increase in size. DXR/CpG-free DNA hydrogels, which could slowly release DXR, were also effective and DXR/CpG DNA hydrogels showed 
the best results. 
 
4. Discussion 
 Hydrogels are one of the best systems for sustained or controlled drug delivery, and a variety of natural or synthetic compounds have 
been used for the preparation of hydrogels with diverse characteristics [17]. An important property of such drug delivery systems is 
biodegradability. DNA hydrogels [16] can be completely made from natural materials, i.e., DNA, so there should be little concern about safety 
and accumulation issues. The gel strength can be controlled by the shape of the DNA units, and X-DNA was found to be good for obtaining rigid 
hydrogels compared with Y- or T-DNA [16]. In the present study, we found that the addition of DXR to DNA hydrogels increased the gel 
fraction and reduced the gel degradation rate (Fig. 6). DXR intercalates between adjacent DNA base pairs, and interferes with DNA strand 
separation. These properties of DXR explain why the DXR/DNA hydrogels had a higher gel fraction compared with DNA hydrogels without 
DXR. Sustained delivery of anticancer agents, such as DXR, has been examined as an efficient and safe treatment for cancer [22]. The DNA 
hydrogels prepared were found to possess properties characteristic of hydrogels, including the controlled release of incorporated DXR. 
 Unlike most hydrogels, DNA hydrogels can be immunologically active when they contain immunostimulatory sequences. DNA 
containing unmethylated CG dinucleotide has been examined for use in cancer immunotherapy in combination with anticancer agents [23] or 
antigens [24]. Although phosphorothioate CpG DNA is generally used for this purpose because of resistance to degradation, it has been reported 
that phosphorothioate DNA induces contact hypersensitivity [25] and toxic shock [26]. Therefore, natural phosphodiester DNA was used in the 
present study to develop DNA hydrogels, although the incorporation of phosphorothioate DNA was found to increase the immunostimulatory 
activity of CpG DNA when built into Y-DNA [Matsuoka et al., submitted]. 
 The immunostimulatory activity of CpG DNA is based on the interaction with TLR9, which is expressed in dendritic cells, B cells and 
other cells [8]. Because the TLR9 is localized in the endosomes, the vesicular compartment within cells, CpG DNA should be internalized via 
endocytosis to come into contact with the receptor. Although the precise mechanism of cellular uptake of DNA hydrogels needs further study, the 
results on the maturation of DC2.4 cells clearly showed that CpG DNA hydrogels can activate cells in a manner which is dependent on the 
presence of CpG motifs (Fig. 4). DNA hydrogels were degraded with time and the components were released into the supernatant when 
incubated in mouse serum. Thus, DNA hydrogels are degraded into pieces small enough to be taken up by cells via endocytosis. The results of 
TNF- release from RAW264.7 cells raise an interesting hypothesis that DNA hydrogels or their degraded materials are more efficient than CpG 
X-DNA in stimulating TLR9-positive cells (Fig. 4A). These results are in good agreement with other DNA preparations with many branches, 
such as Y-shape [14], X-shape (Fig. 2A) and dendrimer-like structures [15]. 
 The precise mechanism whereby these branched DNA preparations are more potent than single- or double stranded DNA is presently 
unknown, but some possibilities can be considered based on previous observations. The uptake of DNA by splenic dendritic cells, B cells and 
peritoneal macrophages was increased by insertion of a polyG sequence, which resulted in the formation of higher-order structures of DNA [27]. 
Cross-linking of two DNAs increased the expression of NF-κB and the production of cytokines [28]. This structure-dependent increase in the 
activity of DNA could be partly explained by increased interaction of DNA with TLR9, because DNA with a high-order structure efficiently 
induced TLR9 crosslinking [27]. Furthermore, the high-mobility group box 1 (HMGB1), a CpG DNA-binding protein that shuttles in and out of 
immune cells and interacts with TLR9 to regulate inflammatory responses, has been reported to bind preferentially to DNA with a high order 
structure, such as 4-way junction DNA [29]. Therefore, the increased immunostimulatory activity of CpG X-DNA and CpG DNA hydrogels 
could be probably associated with its stronger binding to HMGB1. Further studies are required to confirm this hypothesis. 
 The sequence of DNA was new and designed according to the rules and criteria for the immunostimulatory activity of DNA [16,19]. 
Accordingly, CpG-free X-DNA, which has many CG dinucleotides but no potent CpG motifs, was also prepared. The sequences like CCG and 
CGG, which are in the CpG-free X-DNA, are known to be neutralizing CpG motifs that block immune activation by CpG DNA. We found that 
neither CpG-free X-DNA nor CpG-free DNA hydrogels stimulate immune cells (Fig. 2A, 4E), indicating that the DNA hydrogel-induced 
responses are completely due to the presence of CpG motifs. 
 DXR, an anthracycline frequently used in the treatment of breast cancer, was selected as a model drug to be incorporated into X-DNA 
and DNA hydrogels, because it can be intercalated into DNA [30]. In a previous study [11], we used plasmid DNA to deliver DXR to metastatic 
tumor tissues. Because tumor tissues are enriched with immune cells, such as dendritic cells and macrophages [31], DNA can be recognized by 
these cells and induce the release of anticancer cytokines, such as IL-12, from the cells. DXR is considered to be released from these cells and 
reach adjacent cancer cells, because DXR is chemically stable and has been reported to be released from macrophages in tumor tissues after 
administration as DXR containing liposomes [32]. Although this assumption needs further confirmation, it is supported by experimental results 
using a DXR/plasmid DNA complex [11] or DXR/CpG X-DNA (Fig. 5). Addition of DXR/CpG X-DNA to RAW264.7 cells resulted in no 
significant death of RAW264.7 cells in terms of the cell number measured by MTT assay (data not shown). The higher cytotoxic activity of 
DXR/CpG X-DNA compared with DXR/CpG-free X-DNA demonstrated that CpG motif-mediated production of soluble factors, probably 
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antitumor cytokines, is effective in inhibiting the proliferation of colon26/Luc cells. Similar results were obtained after intratumoral injections of 
DXR/DNA hydrogels to tumor-bearing mice (Fig. 7). In this model, DXR and CpG DNA showed at least additive effects on tumor growth. 
 
5. Conclusion 
 The present study demonstrates that DNA hydrogels are effective drug delivery systems that achieve sustained delivery of not only 
anticancer agents but also immunostimulatory signals. These findings will open up a wide range of applications of DNA, a natural, 
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Table 1  The sequences of ODNs used for the preparation of X-DNA. 
ODN Sequence 
CpG Xa acgt tcgctgacgttgcagaca tcacgttgacgctgtcga 
CpG Xb acgt tcgacagcgtcaacgtga aacgtgaagcgtctgcga 
CpG Xc acgt tcgcagacgcttcacgtt gcagacagacgttgacga 
CpG Xd acgt tcgtcaacgtctgtctgc tgtctgcaacgtcagcga 
CpG-free Xa agct aggcaccgtagtcaatcg ccgatgtgtccaaagcct 
CpG-free Xb agct aggctttggacacatcgg tgctcctaccgtactcct 
CpG-free Xc agct aggagtacggtaggagca gtttcggcatgtccacct 




Fig.1. Preparation of X-DNA. A, Agarose gel electrophoresis of CpG X-DNA, CpG-free X-DNA and their components. Samples 
were run on 3 % agarose gel at 100 V for 45min. Lane 1, CpG Xa; lane 2, CpG Xa and CpG Xb; lane 3, CpG Xa, CpG Xb and 
CpG Xc; lane 4, CpG X-DNA; lane 5, CpG-free Xa; lane 6, CpG-free Xa and CpG-free Xb; lane 7, CpG-free Xa, CpG-free Xb 









Fig. 2. Interaction of X-DNA with RAW264.7 cells. A, TNF- release from RAW264.7 cells after addition of CpG-free X-DNA (open 
bars) or CpG X-DNA (closed bars). TNF- in the supernatant was measured at 8 h after addition of each X-DNA at a 
concentration of 5 g/ml. Results are expressed as mean  SD of three determinations. 
*
P<0.05, significantly different from 
any other DNA preparations. B, Uptake of ss- (open bars), ds- (hatched bars) and X-DNA (closed bars) in RAW264.7 cells. 
RAW264.7 cells were incubated with FITC-labeled DNA for 1 h at indicated concentrations at 37 C. The amounts of DNA 
associated with cells were measured by flow cytometry. Results are expressed as the mean ± SD of three determinations. 
*




Fig.3. FE-SEM images of the inner structure of DNA hydrogels. Images were taken using a field-emission scanning electron 







Fig. 4. Activation of immune cells by CpG DNA hydrogels. A, TNF- release from RAW264.7 cells after addition of CpG X-DNA 
(CpG DNA) or CpG DNA hydrogels (Gel). The numbers in parentheses indicate the initial concentrations of DNA (mM) for the 
preparation of CpG DNA hydrogels. TNF- in the supernatant was measured at 8 h after addition of each DNA at a 
concentration of 20 g/ml. Results are expressed as mean  SD of three determinations. 
*
P<0.05, significantly different from 
CpG X-DNA (CpG DNA). B-E, SEM images of DC2.4 cells after addition of LPS or DNA hydrogels. DC2.4 cells were 
incubated in medium containing (B) no hydrogel, (C) LPS (50 g/ml), (D) CpG DNA hydrogels (20 g/ml) or (E) CpG-free 





Fig. 5. Antiproliferative activity of DXR/DNA complex against colon26/Luc cells. RAW264.7cells and colon26/Luc cells were placed 
in the upper and lower chambers of Transwell plates, respectively, and DNA, DXR or their mixture was added to the upper 
side at a final concentration of 10 g DNA/ml and 1 g DXR/ml. After 48 h, the number of colon26/Luc cells in the lower 
chambers was estimated by measuring the luciferase activity of the cells. Results are expressed as mean  SD of three 
determinations. 
*










Fig. 6. Degradation and DXR release from DNA hydrogels in mouse serum. A, Degradation of DNA hydrogels with or without DXR. 
Gels were incubated in mouse serum at 37 C, and the concentration of DNA in the supernatant was measured. Results are 
expressed as mean  SD of three determinations. 
*
P<0.05, significantly different from DXR-free DNA hydrogels. B, DXR 
release from DXR/DNA hydrogels. Gels were incubated in mouse serum at 37 C, and the concentration of DXR in the 





Fig. 7. Effect of DXR, DNA hydrogels or their complexes on the growth of colon26/Luc tumor in mice. Tumor-bearing mice received 
two intratumoral injections on days 9 and 16 after tumor inoculation. The tumor size was measured with calipers periodically. 
(△) 5% dextrose, (▲) DXR, (○) CpG DNA hydrogels, (□) CpG-free DNA hydrogels, (●) DXR/CpG DNA hydrogels, and (■) 
DXR/CpG-free DNA hydrogels. Results are expressed as mean  SD of four mice. 
 
 
